LAVA Therapeutics (NASDAQ:LVTX) Issues Quarterly Earnings Results

LAVA Therapeutics (NASDAQ:LVTX) announced its quarterly earnings data on Tuesday. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05, Yahoo Finance reports. LAVA Therapeutics had a negative return on equity of 51.90% and a negative net margin of 228.02%.

LAVA Therapeutics Stock Up 3.3 %

Shares of LVTX stock traded up $0.06 during trading hours on Thursday, reaching $1.86. The company had a trading volume of 11,191 shares, compared to its average volume of 751,159. The company has a market cap of $47.15 million, a price-to-earnings ratio of -1.67 and a beta of 0.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.42 and a quick ratio of 7.42. LAVA Therapeutics has a 12 month low of $1.13 and a 12 month high of $6.47. The business has a fifty day simple moving average of $1.93 and a 200-day simple moving average of $2.41.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on LVTX shares. JMP Securities reiterated a “market outperform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a report on Friday, June 28th.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.